Photo Credit: Prostock-Studio

For adults aged 60 or older, RSV vaccination is effective for preventing associated hospitalizations and ED encounters, according to findings published in The Lancet. Katherine Fleming-Dutra, MD, and colleagues assessed the effectiveness of RSV vaccines against RSV-associated hospitalizations and ED encounters among adults aged 60 or older who underwent virus testing from October 2023 to March 2024. Vaccine effectiveness was 80% against RSV-associated hospitalizations and 81% against RSV-associated critical illness (ICU admission, death, or both) in 28,271 hospitalizations for RSV-like illness in adults aged 60 or older without immunocompromising conditions. Vaccine effectiveness was 73% against associated hospitalizations among 8,435 hospitalizations in adults with immunocompromising conditions and 77% against RSV-associated ED encounters in 36,521 ED encounters for RSV-like illness among adults aged 60 or older without an immunocompromising condition. Age groups showed similar effectiveness estimates. “These findings provide additional context regarding the benefit of [RSV] vaccination among adults aged at least 60 years,” Dr. Fleming-Dutra and colleagues wrote.